⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 30, 2026JNCI Journal of the National Cancer Institute

Re: Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

Yu Sg Xiushen Wang Hong Ge

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to assess health-related quality of life in patients with newly diagnosed advanced ovarian cancer undergoing maintenance treatment with olaparib and bevacizumab.
Study design
Evaluation of health-related quality of life assessments
Participants included newly diagnosed advanced ovarian cancer patients
Improved health-related quality of life scores observed with olaparib plus bevacizumab compared to standard treatment
Statistically significant differences in specific quality of life domains
Overall patient satisfaction increased with combination therapy

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Evaluates health-related quality of life in advanced ovarian cancer patients, suggesting implications for treatment approaches.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sg et al. (2026) studied this question.

synapsesocial.com/papers/6a47518c5c29257aa25789f2 https://doi.org/10.1093/jnci/djag212

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)Original Research · 2026 · 1 citations
2Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trialRCT · 2022 · 66 citations
3Economic evaluation alongside the PAOLA-1 /ENGOT-ov25 trial: cost of ovarian cancer and cost-effectiveness of olaparib plus bevacizumab first-line maintenanceRCT · 2026
4A phase IV trial to confirm the efficacy of olaparib in combination with bevacizumab as maintenance frontline treatment of HRD-positive ovarian tumours (IOlanTHe).2024
5Comparison of survival outcomes of Olaparib or Olaparib combine with Bevacizumab in patients with primary high-grade serous ovarian carcinomaCohort Study · 2026

Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose Reduction2026
Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial.2024
NRG-GY036: A phase III trial of one vs. two years of maintenance olaparib, with or without bevacizumab, in patients with <i>BRCA1/2</i> -mutated or homologous recombination deficient (HRD+) ovarian cancer following response to first line platinum-based chemotherapy.2026
Statewide surveillance of colorectal cancer screening using geospatial and Multi-Payer claims dataJNCI Journal of the National Cancer Institute · 2026
Subgroup variations in benefit from telehealth palliative care for advanced lung cancerJNCI Journal of the National Cancer Institute · 2026

More from JNCI Journal of the National Cancer Institute

More from Henan Cancer Hospital